Krazati
My Prescription
Payment
Select pharmacy
$23,789.49
Print or send this coupon to your phone
AlbertsonsPowered byAbout Krazati
Drug Details
Krazati (adagrasib) is a medication prescribed for the treatment of certain cancers, specifically advanced and metastatic non-small cell lung cancer (NSCLC) and colorectal cancer in adults with a specific KRAS G12C mutation. It is particularly used when prior treatments are no longer effective. For NSCLC, Krazati is taken alone, while for colorectal cancer, it is used in combination with Erbitux (cetuximab), an infusion administered weekly or biweekly. This drug functions as a KRAS G12C inhibitor. KRAS is a protein that signals cells to grow and divide. In some cancers, a KRAS G12C mutation causes uncontrolled cell growth. Krazati works by binding to the KRAS protein with this mutation, thereby inhibiting tumor growth. Krazati is conveniently available in oral tablet form, taken twice daily. However, it can cause some side effects such as diarrhea, nausea, and fatigue. Always consult with your healthcare provider to ensure this treatment is appropriate and safe for your condition.
Price history for Krazati
180 Tablets, 200MG
Average retail price for Krazati
Average SaveHealth price for Krazati
Our price history data is based on aggregated prescription data collected from participating pharmacies in America. Our prescription data updates daily to reflect the latest price changes. If you notice a missing data point, it means there wasn't sufficient data available to generate a monetary value for that date.
*Retail prices are based on pharmacy claims data, and may not be accurate when we don't have enough claims.
Krazati dosage forms
| Dosage | Quantity | Price from | Per unit |
|---|---|---|---|
| 200MG | 180 Tablets | $23,789.49 | $132.16 |
Krazati FAQs
Krazati is not classified as chemotherapy or immunotherapy. It is a targeted therapy, specifically a KRAS G12C inhibitor, used in the treatment of certain types of cancer.
Krazati is used for the treatment of non-small cell lung cancer (NSCLC) in patients who have a specific mutation in the KRAS G12C gene. It is typically prescribed when the cancer has spread to other parts of the body or cannot be surgically removed, and after the patient has received at least one prior systemic therapy.
Krazati, also known as adagrasib, is a medication that has shown the ability to shrink tumors in certain patients with specific types of cancer. It is particularly used in cases where tumors have a KRAS G12C mutation. The effectiveness of Krazati in shrinking tumors can vary depending on individual patient factors and the specific characteristics of the cancer. It is important for patients to discuss treatment options and potential outcomes with their healthcare provider.
Krazati is not classified as chemotherapy. It is a targeted therapy medication used to treat certain types of cancer by specifically inhibiting the KRAS G12C mutation.
The cost of Krazati can vary depending on factors such as the pharmacy, location, insurance coverage, and any available discounts or assistance programs. It is recommended to contact a local pharmacy or healthcare provider for the most accurate and up-to-date pricing information. Additionally, patients may inquire about financial assistance programs that could help reduce the cost.